MM Packaging to Become a Standalone Company

MM Group to Retain 30% Ownership Interest

NEW YORK, Nov. 10, 2026 /PRNewswire/ — KPS Capital Partners, LP (“KPS”) has signed a definitive agreement to acquire MM Packaging (the “Business”) from Mayr-Melnhof Karton AG (“MM Group”) for an enterprise value of €2.4 billion. MM Group will retain 30% ownership of the Business. Completion of the transaction is subject to the required corporate and regulatory approvals as well as other customary conditions and for the French Business, the acquisition is subject to consultation processes with workers representatives. Upon closing, MM Packaging will operate as a standalone company and retain the MM Packaging name.

MM Packaging is a global manufacturer of consumer packaging products, including folding cartons, labels and leaflets, for the food and beverage, pharmaceutical and healthcare, beauty and personal care and household care sectors. Headquartered in Vienna, Austria, the Business operates more than 50 production sites across 19 countries and has approximately 8,500 employees. It is the world’s largest producer of secondary pharmaceutical packaging and a leading producer of folding cartons for food in Europe. MM Packaging has long-standing relationships with many of the world’s top food, consumer and pharmaceutical companies, with key customer relationships averaging more than 20 years.

Michael Psaros, Co-Founder and Co-Managing Partner of KPS, said: “MM Packaging is an industry-leading business, and we are excited to take it to the next level as an independent company. We appreciate the trust MM Group is placing in KPS and look forward to our partnership. KPS has had extraordinary success investing in the packaging sector across paper, board and metal substrates. We will leverage our deep industry experience, financial resources, commitment to manufacturing excellence and global presence to drive MM Packaging’s growth.”

Peter Oswald, CEO of MM Group, said: “This transaction will allow MM Packaging to accelerate growth under the leadership of KPS, who has proven their expertise in managing large, global manufacturing and industrial businesses. Our retained shareholding of 30% will enable MM Group to participate in its future value creation under KPS ownership. We are looking forward to our partnership with KPS.”

Paul, Weiss, Rifkind, Wharton and Garrison LLP and Schönherr served as legal counsel and Barclays Bank Ireland plc and Citi served as financial advisors to KPS.

About KPS Capital Partners, LP
KPS, through its affiliated management entities, is the manager of the KPS Special Situations Funds, a family of investment funds with approximately $19.1 billion of assets under management (as of June 30, 2026). For over three decades, the Partners of KPS have worked vigorously to realize significant capital appreciation by making controlling equity investments in manufacturing and industrial companies across a diverse array of industries, including basic materials, branded consumer, healthcare and luxury products, automotive parts, capital equipment and general manufacturing. KPS seeks to create value for its investors by working constructively with talented management teams to make businesses better, and generate investment returns by structurally improving the strategic position, competitiveness and profitability of its portfolio companies, rather than primarily relying on financial leverage. The KPS Funds’ portfolio companies currently generate aggregate annual revenues of approximately $26.1 billion, operate 277 manufacturing facilities in 25 countries, and have approximately 62,000 employees, directly and through joint ventures worldwide (as of June 30, 2026). The KPS investment strategy and portfolio companies are described in detail at www.kpsfund.com.

About MM Group
MM Group is a global leader in fibre-based consumer packaging, committed to enabling people to live better lives on a better planet. With a portfolio that includes cartonboard, folding cartons, kraft and fine papers, leaflets, and labels, MM delivers innovation with recyclability at its core. As a publicly listed company, MM Group combines long-term orientation with clear environmental accountability.

ZEISS Medical Technology showcased at CIIE its next-generation aspheric phakic intraocular lens (pIOL) PT LUNANA^® to address myopia in China, a growing major public health challenge for the region.

• Research shows: China has an estimated 600 million people with myopia; a growing number are entering adulthood with myopia: roughly two in three (67.2%) people aged 15 to 19 have myopia and 9.5% have high myopia, according to a recent systematic review.1

• China’s National Medical Products Administration (NMPA) has approved ZEISS PT LUNANA, the first in the Phakic Technology (PT) family of phakic IOLs.
• CIIE unveiling: ZEISS showcased the PT LUNANA pIOL at the 9th China International Import Expo (CIIE) in Shanghai, China.
• In China, for Global: Prioritizing its mission to develop innovative solutions in China, the new ZEISS PT LUNANA pIOL was developed by Wuxi Carl Zeiss Vision Pro Medical Technology Co., Ltd, a joint venture of ZEISS in China, and is set to be manufactured locally.

JENA, Germany, Nov. 10, 2026 /PRNewswire/ — ZEISS Medical Technology, one of the world’s leading medical technology companies, announced its plans to extend ZEISS’s established portfolio of solutions for addressing myopia with the recent approval from the National Medical Products Administration (NMPA) in China for the PT LUNANA^® phakic IOL from ZEISS.

NMPA approval represents the company’s first step in establishing the ZEISS phakic IOL portfolio. ZEISS PT LUNANA pIOL brings together ZEISS’s cutting-edge optical technology and global ophthalmic workflow leadership with local expertise, R&D and manufacturing capabilities. ZEISS showcased its new pIOL at the 9th China International Import Expo (CIIE) in Shanghai, China, with plans for its release in the coming year. ZEISS PT LUNANA pIOL features a next-generation aspheric optical design, AQUAFLEX^® hydrophilic polymer material and a broad selection of lens sizes and power options.

“As the impact of myopia continues to grow in China, advancing new solutions has never been more important. ZEISS PT LUNANA reflects our commitment to address this need through continued innovation, expanded treatment options and by enabling a more personalized approach to vision correction,” says Andreas Völker, Head of the Ophthalmology Strategic Business Unit, ZEISS Medical Technology. “The approval of ZEISS PT LUNANA represents more than a product milestone; it underscores our ambition to innovate in China and help shape a future where more people have access to advanced solutions for myopia.”

“The strong momentum of the Chinese market is driving ZEISS’s ‘In China, for Global’ innovation strategy,” says Martin Fischer, President and CEO of ZEISS Greater China. “As we work with local partners to build an open and collaborative innovation ecosystem, ZEISS PT LUNANA exemplifies the success of this approach, combining breakthrough optical design with local agile responsiveness to support higher standards of vision health.”

Myopia is a major public health challenge in China

China has an estimated 600 million people with myopia, with particularly strong demand for refractive surgery among young and middle-aged adults. As a growing number of young people enter adulthood with moderate-to-high myopia, the need for individualized refractive-care pathways will only grow. Recent research shows that two in three (67.2%) people aged 15 to 19 in China have myopia, with 9.5% having high myopia, according to a recent systematic review.¹ 

The Work Plan for Accelerating the Provision of High-Quality and Efficient Eye Health Services (2026-2030) calls for increased coverage of effective refractive error correction. As one of the mainstream procedures for refractive correction, phakic IOL surgery has undergone more than three decades of clinical validation and gained widespread recognition among physicians and patients. However, as expectations increase for visual quality, demand for surgical options and interest in alternatives continue to rise, options for advanced phakic IOLs remain relatively limited. ZEISS PT LUNANA pIOLs were developed to address this gap, offering myopic patients in China a new, personalized option for refractive correction.

The ZEISS PT LUNANA pIOL is the first step in establishing a broader phakic IOL portfolio, driven by the company’s rich optical heritage combined with local expertise and R&D. The first public showing at the CIIE marks the company’s plans to expand its comprehensive refractive solutions, providing physicians with more vision correction options for a wider group of patients.

“Since the introduction of phakic IOLs, both physicians and patients have been looking forward to more diverse and innovative products and technologies. The debut of ZEISS PT LUNANA in China in the coming year will not only allow patients to benefit from this innovation firsthand but also will provide ophthalmologists with an opportunity to gain valuable clinical experience early on and strengthen their influence in cutting-edge academic research,” said Professor Zhou Xingtao, President of the Eye and ENT Hospital of Fudan University, Shanghai.

ZEISS to extend refractive portfolio, expanding options for high-quality vision

ZEISS offers options for managing myopia throughout a person’s lifetime, from Myocare^® lenses for children, Ortho-K lenses, and glasses through to refractive correction, such as SMILE pro^® from ZEISS, and intraocular lenses. Patients seeking refractive correction options who are not suitable for laser correction may face challenges in finding a suitable solution for their individual eye conditions. ZEISS PT LUNANA integrates aspheric optical design into its next generation phakic IOL and features AQUAFLEX hydrophilic polymer material, designed for flexibility, clarity and stability. The phakic IOL will accommodate a wide range of myopia levels, as well as benefit and may provide a refractive correction option for patients with thin corneas or high myopia, who may not be candidates for laser vision correction.

Each patient’s eyes are unique, making precise, individualized fitting essential for phakic IOLs. Professor Wang Xiaoying, Chief Physician at the Eye and ENT Hospital of Fudan University in Shanghai, emphasized that the ZEISS PT LUNANA pIOL offers a considered selection of seven lens sizes and 0.25-diopter increments, enabling physicians with greater choice when selecting a lens for individual patient needs. She added, “It supports physicians in their procedures and can help patients feel confident in their treatment choice.”

Michael Achtelik, Global Head of Business Sector, Refractive Lasers, ZEISS Medical Technology, explained, “The NMPA approval in China marks an important step in our journey to bring the ZEISS phakic IOL portfolio to ophthalmic customers worldwide. By combining ZEISS’ global expertise in precision optics and refractive workflows with local manufacturing expertise and market insights close to our customers in China, we are strengthening our ability to deliver more personalized solutions for patients across China.”

ZEISS PT LUNANA has completed pre-market clinical trials and two years of follow-up at nine Grade 3A hospitals in China. ZEISS plans to commercialize this product in China first in 2027 and eventually will bring the platform to the global stage.

^1. Pan W, Saw SM, Wong TY, Morgan I, Yang Z, Lan W. Prevalence and temporal trends in myopia and high myopia children in China: a systematic review and meta-analysis with projections from 2020 to 2050. Lancet Reg Health West Pac. 2025 Jan 27;55:101484. doi: 10.1016/j.lanwpc.2025.101484

PT LUNANA and AQUAFLEX are trademarks of Carl Zeiss Meditec AG. Trademark registration status may vary by country. 

Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals’ content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support.

Contact for investors
Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220 116
Mail: investors.med@zeiss.com

Contact for the press
Frank Smith
Head of Global Communications
Ophthalmology, Carl Zeiss Meditec AG
Phone: +49 3641 220 331
Mail: press.med@zeiss.com

Company Profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the TecDAX and SDAx of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,784 employees worldwide, the Group generated revenue of €2,228m in fiscal year 2024/25 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company’s presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG’s shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For further information visit: www.zeiss.com/med.

Awards Highlight Luxury Hospitality and Fine Dining Excellence Across South Korea and Vietnam

• The Shilla Seoul earns Global Winner recognition for Best Luxury Culinary Hotel, alongside national honors for luxury city and wedding hotels
• La Yeon and Continental at The Shilla Seoul receive Global Winner honors for Korean cuisine and wine selection, respectively
• The Shilla Jeju wins three resort categories across Asia, East Asia and South Korea
• Shilla Monogram Danang is named Global Winner for Best Luxury Beach Resort, highlighting the group’s growing international presence

SEOUL, South Korea, Nov. 10, 2026 /PRNewswire/ — The Shilla Hotels & Resorts has earned 11 awards, including four Global Winner honors, at the 2026 World Luxury Awards, recognizing its excellence across luxury hotels, fine dining and resort experiences. The awards recognize The Shilla Seoul and its restaurants, La Yeon and Continental, and The Shilla Jeju in South Korea, alongside Shilla Monogram Danang in Vietnam.

The World Luxury Awards recognize excellence across the luxury hospitality and travel industries through dedicated award programs for hotels, spas, restaurants and travel. The World Luxury Hotel Awards, established in 2006, and the World Luxury Restaurant Awards, established in 2015, recognize outstanding properties and dining establishments through online voting. Winners are selected across global, continental, regional and country categories.

The Shilla Seoul was named Global Winner in the Best Luxury Culinary Hotel category, while also receiving Best Luxury Wedding Hotel in South Korea and Best Luxury City Hotel in South Korea honors. The three awards recognize the hotel’s offerings across fine dining, weddings and luxury urban hospitality, reflecting the breadth of experiences available at the property.

The Shilla Seoul’s culinary recognition was further strengthened by its restaurants, La Yeon and Continental, which each earned Global Winner honors. La Yeon, the hotel’s Korean restaurant, received the Best Korean Cuisine Global Winner award and was also recognized as Best Luxury Heritage Restaurant in East Asia. Continental, its French restaurant, was named Global Winner for Best Wine Selection and received the Best French Cuisine award in East Asia. Together with The Shilla Seoul’s Best Luxury Culinary Hotel recognition, these awards highlight the hotel’s strengths across Korean and French fine dining.

The Shilla Jeju received three awards: Best Luxury Ocean View Resort in Asia, Best Luxury Resort in East Asia and Best Luxury Family Resort in South Korea. Set against Jeju Island’s scenic coastal landscape, the resort offers luxury accommodations, diverse dining options and leisure experiences designed for a relaxing island getaway. The three awards underscore its appeal to a broad range of travelers, from couples seeking a peaceful retreat to families enjoying a memorable resort vacation.

In Vietnam, Shilla Monogram Danang was named Global Winner in the Best Luxury Beach Resort category, marking another kind of international recognition for The Shilla Hotels & Resorts. Shilla Monogram is a lifestyle hotel brand that combines The Shilla’s hospitality heritage with the distinctive character of each destination, offering experiences shaped by local culture and surroundings. The award demonstrates the group’s ability to bring its hospitality expertise to international markets through a distinct brand experience.

The recognition across city hotels, fine dining restaurants and resort destinations reflects the breadth of The Shilla Hotels & Resorts’ hospitality expertise. Across its portfolio, the group combines a longstanding commitment to refined service and exceptional guest experiences with hospitality offerings tailored to different destinations and traveler needs.

“We are delighted that The Shilla Seoul and The Shilla Jeju have been recognized for their excellence in luxury hospitality, and it is particularly meaningful to see Shilla Monogram Danang receive global recognition as well,” said a spokesperson for The Shilla Hotels & Resorts. “This achievement shows how the hospitality expertise we have developed in Korea, combined with the unique character of each destination, can create experiences that resonate with international travelers. We will continue to build on this approach as we expand into new markets.”

The Shilla Hotels & Resorts continues to strengthen its international presence, building on the hospitality expertise developed through its operations in South Korea. As part of its ongoing global expansion, the group opened Shilla Monogram Hanoi Westlake in Vietnam in October 2026, further extending its hospitality offerings to travelers around the world.

For more information:

The Shilla Hotels & Resorts Official Website: https://www.shillahotels.com/en/shillahotels/hub/index.do

The 20th Annual World Luxury Hotel Awards: The 20th Annual World Luxury Hotel Awards – World Luxury Hotel Awards

The 11th Annual World Luxury Restaurant Awards: https://www.luxuryrestaurantawards.com/winner/the-11th-annual-world-luxury-restaurant-awards/?sorts%23winners-table%5brestaurant%5d=1

About Hotel Shilla

Hotel Shilla, an affiliate of the Samsung Group, is a leading hospitality and travel retail operator based in South Korea, committed to delivering outstanding customer experiences through innovation and service excellence. Its hospitality division, The Shilla Hotels & Resorts, includes three hotel brands: The Shilla, Shilla Monogram, and Shilla Stay, with 23 properties across South Korea, China and Vietnam. The Shilla Seoul, the company’s flagship luxury property, is a member of the Leading Hotels of the World (LHW) and an APAC Regional Program Partner of Virtuoso, recognized globally for excellence in service and sophistication. In its travel retail division, The Shilla Duty Free is a leading duty-free powerhouse, operating three domestic stores, two overseas branches, and an online platform. Drawing on decades of expertise, Hotel Shilla continues to pursue new opportunities for growth, aiming to become a world-class service distribution leader.

DUBAI, UAE, Nov. 9, 2026 /PRNewswire/ — The inaugural Dubai Future Finance Week concluded on 6 November, bringing together financial institutions, regulators and innovators alongside 1,000 speakers across 85 side events, 13 signature forums and 16 stages in Dubai. Led by Dubai International Financial Centre (DIFC), the leading global financial centre in the Middle East, Africa and South Asia (MEASA) region, the week delivered more than 80 partnerships and more than 100 strategic announcements, establishing an annual meeting point for the global financial industry and advancing the Dubai Economic Agenda D33 goal of positioning the city among the world’s top four financial centres.

Held under the overarching theme of “Finance Reimagined: Where Innovation Meets Policy and Purpose,” the week included the Dubai FinTech Summit as the anchor event, alongside the Future Sustainability Forum, the Future Islamic Finance Forum, the Dubai Family Wealth Summit, the Future Tokenisation Forum, IPEM Future Dubai, the Capital Exchange GP-LP Programme, the Investment Leaders Exchange, GAIP InsureTek Middle East, the MENA Banking Excellence Awards and the DealCatalyst Fixed Income Alternatives series.

DIFC confirmed that it is now home to more than 2,000 AI, FinTech and innovation companies and a wealth and asset management community surpassing 600 firms.

DIFC announced plans to launch the Dubai FinTech Stack, an initiative designed to give founders access to the essential capabilities needed to establish, operate and scale their businesses, from customer onboarding and payments to risk management, financial security and AI integration.

Additionally, DIFC Academy will expand by tenfold to 370,000 sq. ft. within DIFC Zabeel District, transforming into a purpose-built academic campus with capacity for 50,000 learners annually from 2030.

To develop the next generation of family-enterprise leaders, DIFC announced a 2027 NextGen Internship Programme under the Dubai Family Wealth Centre, placing participants within DIFC firms.

The DIFC Innovation Hub also announced plans to establish the Islamic Finance Innovation Centre, which will serve as a collaborative, global platform connecting financial institutions with regulators, Shariah scholars, standards bodies, FinTechs and technology companies.

Ignyte, Dubai’s official start-up ecosystem platform operating under DIFC signed several partnerships to develop market-ready solutions, advance Web3 innovation and offer access to banking services for associated start-ups and founders.

In 2027, Dubai Future Finance Week will return for its second edition in May 2027.